Australian Clinical Labs Limited (ASX: ACL)

Market Cap	666.59M
Revenue (ttm)	696.37M
Net Income (ttm)	23.93M
Shares Out	198.98M
EPS (ttm)	0.12
PE Ratio	27.92
Forward PE	17.39
Dividend	0.12 (3.54%)
Ex-Dividend Date	Sep 4, 2024

Volume	783,680
Average Volume	387,774
Open	3.360
Previous Close	3.350
Day's Range	3.340 - 3.490
52-Week Range	2.140 - 3.855
Beta	1.15
RSI	40.17
Earnings Date	Feb 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,900
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.